Teriflunomide (NAT-Teriflunomide)
Immunomodulator (pyrimidine synthesis inhibitor)
Teriflunomide (NAT-Teriflunomide)
Forms and strengths
Form: TabletStrength: 14 mg
References
Indication
- Teriflunomide is used as a single agent (monotherapy) to treat relapsing forms of multiple sclerosis, reducing the frequency of relapses and slowing the buildup of physical disability.
- Teriflunomide should only be prescribed by clinicians experienced in diagnosing and managing multiple sclerosis.
Pregnancy
Contraindicated in pregnancy. Confirm pregnancy status and discuss alternative therapy with the prescriber before dispensing.
- Teriflunomide is contraindicated during pregnancy because animal studies show it can cause fetal death or birth defects at doses lower than those used in humans.
- Pregnancy must be ruled out with a negative pregnancy test before starting teriflunomide, and women of childbearing potential must use reliable contraception throughout treatment.
- Teriflunomide is eliminated from the body very slowly, so anyone planning a pregnancy after stopping treatment should undergo an accelerated elimination procedure first to lower drug levels quickly.
- If pregnancy occurs during treatment, teriflunomide should be stopped immediately, an accelerated elimination procedure started, and the patient referred for specialized obstetric counselling.
Breastfeeding
- Teriflunomide passes into milk in animal studies, and it is not known whether it passes into human breast milk.
- Because of the potential for serious harm to a nursing infant, a decision should be made to either stop breastfeeding or stop teriflunomide, weighing how important the drug is to the mother.
Geriatrics
- Clinical trials of teriflunomide did not include patients over 65 years of age, so it should be used with caution in this age group.
- Older adults are more likely to have other illnesses and take other medications, which may call for closer monitoring during teriflunomide treatment.
Pediatrics
- Teriflunomide's safety and effectiveness have not been established in patients under 18, and it is not recommended for this age group.
- In a pediatric multiple sclerosis trial, pancreatitis, hair loss, infections, and tingling sensations were reported more often than in adult trials.
Dosage & Administration
- The recommended dose of teriflunomide for adults is 14 mg by mouth once daily, taken with or without food.
- No dose adjustment is needed for mild or moderate liver impairment, but teriflunomide is contraindicated in severe liver impairment.
- No dose adjustment is needed for severe kidney impairment, although teriflunomide has not been studied in patients on dialysis and is not recommended for them.
- Before starting treatment, blood pressure, liver enzymes and bilirubin, a complete blood count, and screening for latent tuberculosis should all be checked.
- Liver enzyme (ALT) levels should be monitored at least monthly for the first six months of treatment.
- If a dose is missed, the next dose should simply be taken as scheduled; doses should not be doubled.
Overdose
If overdose is suspected, seek emergency medical attention immediately or contact your regional Poison Control Centre without delay.
- There is no reported human experience with symptomatic teriflunomide overdose.
- Doses of 70 mg daily for up to 14 days were well tolerated by healthy volunteers in studies.
- If a clinically relevant overdose or toxicity occurs, cholestyramine or activated charcoal is used to speed up elimination of the drug from the body.
Common side effects
- Diarrhea may occur.
- Nausea may occur.
- Hair thinning or hair loss (alopecia) may occur, usually diffuse rather than complete, and typically improves while still on treatment.
- Headache may occur.
- Tingling or numbness (paraesthesia) may occur.
- A mild rise in blood pressure may occur.
- Influenza-like illness may occur.
- Sinusitis may occur.
- Upper abdominal pain may occur.
- Toothache may occur.
- Mild, usually temporary reductions in blood phosphorus levels may occur.
- Elevated liver enzymes (ALT) may occur, usually within the first six months of treatment.
Serious side effects
Serious side effects require immediate discussion with the prescriber or emergency care.
- Severe liver injury, including rare cases of fatal liver failure, has occurred.
- Interstitial lung disease, including acute inflammation of the lungs, has been reported and can be life-threatening.
- Pulmonary hypertension, including fatal cases, has been reported.
- Serious skin reactions such as Stevens-Johnson syndrome, toxic epidermal necrolysis, and drug reaction with eosinophilia and systemic symptoms (DRESS) have occurred, sometimes fatally.
- Acute pancreatitis has been reported, more often in pediatric patients than adults.
- Significant reductions in white blood cells, including neutropenia, may occur and increase infection risk.
- Peripheral neuropathy, felt as numbness or tingling in the hands or feet, may develop and may not fully resolve even after stopping treatment.
- Severe hypersensitivity reactions, including anaphylaxis and angioedema, have been reported.
- New-onset or worsening psoriasis, including pustular psoriasis, has been reported.
- Seek urgent medical attention for yellowing of the skin or eyes, dark urine, unexplained nausea or abdominal pain, persistent cough or shortness of breath, severe skin blistering or peeling, or swelling of the face, lips, tongue, or throat.
Use with caution
- Use with caution in patients with pre-existing liver disease, since baseline liver enzymes should be checked and monitored closely during treatment.
- Use with caution in patients with reduced kidney function undergoing dialysis, as this population has not been studied.
- Use with caution in patients over 65, who were not included in clinical trials.
- Use with caution in patients with a history of peripheral neuropathy, diabetes, or those taking other neurotoxic medications, which increase the risk of nerve damage.
- Use with caution in patients with pre-existing lung disease, given the risk of interstitial lung disease.
- Use with caution in patients switching to or from other multiple sclerosis therapies that suppress the immune system, such as natalizumab, fingolimod, or alemtuzumab, due to overlapping effects on blood cell counts.
- Use with caution in patients due for vaccination, since live vaccines are not recommended during treatment or for some time after stopping.
- Use with caution in patients with a rare hereditary intolerance to galactose or lactase deficiency, since the tablets contain lactose.
- Screen for latent tuberculosis and treat any active infection before starting teriflunomide.
Contraindications
- Contraindicated in patients with known hypersensitivity to teriflunomide, to leflunomide, or to any ingredient in the tablet.
- Contraindicated in patients currently being treated with leflunomide.
- Contraindicated in patients with severe liver impairment.
- Contraindicated in pregnant women or women of childbearing potential not using reliable contraception.
- Contraindicated in patients with immunodeficiency states, such as AIDS.
- Contraindicated in patients with significant bone marrow impairment or significant anemia, leukopenia, neutropenia, or thrombocytopenia.
- Contraindicated in patients with serious, active infections.
Drug interactions
- Concurrent use with leflunomide is contraindicated because teriflunomide is leflunomide's active metabolite.
- Teriflunomide increases blood levels of CYP2C8-metabolized drugs such as repaglinide, paclitaxel, pioglitazone, and rosiglitazone; these should be used with monitoring.
- Teriflunomide increases blood levels of oral contraceptive hormones, so the type or dose of oral contraceptive used may need reconsideration.
- Teriflunomide can reduce the effectiveness of CYP1A2-metabolized drugs such as duloxetine, theophylline, and tizanidine.
- Teriflunomide decreases the INR response to warfarin, so closer INR monitoring is recommended when the two are combined.
- Teriflunomide increases blood levels of OAT3-transported drugs such as cefaclor, penicillin G, ciprofloxacin, indomethacin, ketoprofen, furosemide, cimetidine, methotrexate, and zidovudine.
- Teriflunomide increases blood levels of statins and other transporter substrates such as rosuvastatin, simvastatin, atorvastatin, and methotrexate; if rosuvastatin is used together, its dose should not exceed 10 mg once daily.
- Inhibitors of the BCRP transporter, such as cyclosporine, eltrombopag, and gefitinib, may increase teriflunomide levels in the body.
- Combining teriflunomide with other potentially liver-toxic drugs may increase the risk of liver injury.
- Combining teriflunomide with antineoplastic or other immunosuppressive therapies is not recommended because of the potential for added effects on the immune system.
- Cholestyramine or activated charcoal is used deliberately to speed elimination of teriflunomide when rapid clearance is needed, such as before pregnancy or after a serious adverse reaction.
Food interactions
- Food has no meaningful effect on how teriflunomide is absorbed, so it can be taken with or without food.
Time of administration
- Teriflunomide is taken once daily at any convenient time, with or without food.
Storage
- Store teriflunomide tablets at 15°C to 30°C.
- Keep tablets in blister packaging until ready to use, and discard any tablets from a bottle 90 days after opening.
Patient take-away
- Teriflunomide is a once-daily pill that helps reduce relapses and slow disability progression in relapsing multiple sclerosis.
- Regular blood tests are needed to monitor liver function and blood counts, especially in the first six months of treatment.
- Women of childbearing potential must use reliable contraception during treatment and confirm they are not pregnant before starting.
- Report any signs of liver problems, unexplained infection, numbness or tingling, or breathing difficulty to a healthcare professional promptly.
- Teriflunomide stays in the body for a long time after stopping, so an accelerated elimination procedure may be needed if a rapid washout is required.